Related Experiment Video

Updated: Aug 23, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K

First-line treatment and overall survival in EGFR mutation-positive advanced non-small cell lung cancer: a national

L-Y Huang1, H-P Chang, R-Y Chang

  • 1Division of Health Technology Assessment, Center for Drug Evaluation, Taipei, Taiwan. lyhuang277@cde.org.tw.

European Review for Medical and Pharmacological Sciences
|October 31, 2022
PubMed
Abstract

Insights

First-line targeted therapy significantly improves overall survival for advanced EGFR-positive non-squamous non-small cell lung cancer (NSCLC) patients in Taiwan compared to chemotherapy alone.

Area of Science:

  • Oncology
  • Clinical Research
  • Epidemiology

Background:

  • Non-squamous non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality in Taiwan.
  • Epidermal growth factor receptor (EGFR) mutations are common in NSCLC, driving targeted therapy development.

Purpose of the Study:

  • To evaluate the real-world effectiveness of first-line targeted therapy versus chemotherapy for advanced EGFR mutation-positive non-squamous NSCLC in Taiwan.
  • To compare overall survival (OS) outcomes between treatment groups.

Main Methods:

  • Retrospective, observational study of 63,248 advanced non-squamous NSCLC patients in Taiwan (2002-2019).
  • Compared patients receiving first-line targeted therapy (n=19,458) with those receiving chemotherapy alone (n=22,994 for 2011-2019; n=20,796 for 2002-2010).
  • Overall survival (OS) was the primary endpoint.

Main Results:

  • Median OS for targeted therapy was 22.9 months versus 11.7 months for chemotherapy alone.
  • Targeted therapy demonstrated a significant survival benefit (Hazard Ratio: 0.521, p<0.001).

Conclusions:

  • First-line targeted therapy offers superior survival outcomes for Taiwanese patients with advanced EGFR mutation-positive non-squamous NSCLC.
  • These findings support the clinical utility of targeted therapy in this patient population in Taiwan.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K